Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Amortization of Deferred Charges (2022 - 2025)

Arcutis Biotherapeutics has reported Amortization of Deferred Charges over the past 4 years, most recently at $461000.0 for Q4 2025.

  • Quarterly results put Amortization of Deferred Charges at $461000.0 for Q4 2025, down 82.24% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 67.51% YoY), and the annual figure for FY2025 was $1.8 million, down 67.51%.
  • Amortization of Deferred Charges for Q4 2025 was $461000.0 at Arcutis Biotherapeutics, up from $449000.0 in the prior quarter.
  • Over the last five years, Amortization of Deferred Charges for ARQT hit a ceiling of $2.6 million in Q4 2024 and a floor of $392000.0 in Q1 2022.
  • Median Amortization of Deferred Charges over the past 4 years was $898000.0 (2022), compared with a mean of $862250.0.
  • Biggest five-year swings in Amortization of Deferred Charges: soared 155.41% in 2024 and later plummeted 82.24% in 2025.
  • Arcutis Biotherapeutics' Amortization of Deferred Charges stood at $1.0 million in 2022, then changed by 0.0% to $1.0 million in 2023, then skyrocketed by 155.41% to $2.6 million in 2024, then plummeted by 82.24% to $461000.0 in 2025.
  • The last three reported values for Amortization of Deferred Charges were $461000.0 (Q4 2025), $449000.0 (Q3 2025), and $431000.0 (Q2 2025) per Business Quant data.